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To report new sporadic cases and 1 family with epilepsy of infancy with migrating focal seizures
(EIMFSs) due to KCNT1 gain-of-function and to assess therapies’ efficacy including quinidine.
Methods
We reviewed the clinical, EEG, and molecular data of 17 new patients with EIMFS and KCNT1
mutations, in collaboration with the network of the French reference center for rare epilepsies.
Results
Themean seizure onset age was 1month (range: 1 hour to 4months), and all children had focal
motor seizures with autonomic signs and migrating ictal pattern on EEG. Three children also
had infantile spasms and hypsarrhythmia. The identified KCNT1 variants clustered as “hot
spots” on the C-terminal domain, and all mutations occurred de novo except the p.R398Q
mutation inherited from the father with nocturnal frontal lobe epilepsy, present in 2 paternal
uncles, one being asymptomatic and the other with single tonic-clonic seizure. In 1 patient with
EIMFS, we identified the p.R1106Q mutation associated with Brugada syndrome and saw no
abnormality in cardiac rhythm. Quinidine was well tolerated when administered to 2 and
4-year-old patients but did not reduce seizure frequency.
Conclusions
The majority of the KCNT1 mutations appear to cluster in hot spots essential for the channel
activity. A same mutation can be linked to a spectrum of conditions ranging from EMFSI to
asymptomatic carrier, even in the same family. None of the antiepileptic therapies displayed
clinical efficacy, including quinidine in 2 patients.
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Epilepsy of infancy with migrating focal seizures (EIMFS) is
a rare and severe epileptic syndrome characterized by (1) sei-
zure onset during the first months of life, (2) focal seizures
migrating from one cortical region to another, (3) marked
pharmacoresistance, and (4) severe cognitive long-term
disability.1,2 In 50% of patients with EIMFS, gain-of-function
mutations are identified in the KCNT1 gene (OMIM608167),
encoding the sodium-activated potassium channel.3 KCNT1
mutations result in a severe form of autosomal dominant
nocturnal frontal lobe epilepsy (ADNFLE),4 in some patients
with other developmental and epileptic encephalopathies,5–8 in
patients with focal and multifocal epilepsies,9,10 and patients
with no seizures but presenting with cardiac arrhythmia.11
Genotype-phenotype correlations are rather complicated due
to the association of the same KCNT1mutation with different
epilepsy phenotypes.9 Additional studies are necessary to
evaluate the spectrum of phenotypes caused by KCNT1
mutations and for correlation of phenotype-genotype.
In addition, the identification of KCNT1 mutations could
have therapeutic implications because quinidine rescues the
K+ channel gain-of-function effect of the mutation as shown
by in vitro studies.12 Although the clinical use of quinidine is
controversial, administration of quinidine resulted in varying
degrees of efficacy in some patients.8,13–21
We report a new series of 17 patients with EIMFS and
KCNT1 mutations, pointing out intrafamilial phenotype
heterogeneity in a 3-generation family. We discuss genotype-
phenotype correlations based on this new case series and the
previously reported cases in the literature.
Methods
Seventeen patients with EIMFS and KCNT1 mutations were
collected through a multicentric study in the hospitals of the
network of reference centers for rare epilepsies in France and
Spain. The EIMFS diagnosis was according to the following
criteria: (1) onset under age 6 months, (2) presentation with
focal seizures progressing to frequent or almost continuous
polymorphous seizures with a migrating pattern; and (3)
developmental arrest at seizure onset and progressive cogni-
tive decline.1,2
We collected the clinical and EEG data, including family
history of seizure disorders, psychomotor development eval-
uation, seizure onset and type, EEGs recordings with video
monitoring, neurologic examination, neuroimaging studies,
and response to antiepileptic drugs (AEDs).
The KCNT1 mutation detection was by using Sanger se-
quencing or next-generation sequencing panels targeting 71
to 151 genes involved in childhood epilepsies (table e-1,
links.lww.com/NXG/A187). In addition, we reviewed all
KCNT1 reports referenced in PubMed up to 2018. We
compared the genotype-phenotype of the KCNT1 mutations
reported in the literature with special attention on “hotspots.”
Standard protocol approvals, registrations,
and patient consents
All parents or legal guardians gave written informed consent
for genetic diagnostic procedures following the guidelines of
the ethics committee of our institution. Approval for the re-
search protocols was from the local institutional review board
and ethics committee.
Data availability
Anonymized data not published within this article will be
made available by request from qualified investigators.
Results
Clinical and EEG features
In this study, the cohort of patients with KCNT1 mutations
consisted of 8 females and 9 males. Patient demographic data
are shown in the table. Patients did not have any family history
of seizures or neurologic diseases except for patient 2. The
father of patient 2 (II2, figure 1) with a diagnosis of ADNFLE,
had seizure onset during adolescence. He was seizure-free on
antiepileptic treatment since age 17 years and had a healthy
social and professional integration. One of the patient 2 pa-
ternal uncles (II3, figure 1) presented with a single un-
provoked generalized tonic-clonic seizure at age 25 years. He
had a healthy social and professional life and did not receive
any treatment. Patient 2 paternal grandfather (I2, figure 1)
likely had severe ADNFLE since he experienced nocturnal
paroxysmal events and psychiatric and behavioral problems
during adulthood (figure 1).
The birth of all 17 patients was uneventful after full-term
pregnancies except for a premature spontaneous delivery at
34 weeks of gestation without perinatal distress in patient 15,
and patient 16 showed intrauterine growth delay and poly-
hydramnios. Seizures occurred at a mean age of 1 month
(range: 1 hour to 4 months), within the first week of life for 6
patients (#5, 6, 7, 9, 10, and 11), and all children presented
with focal motor seizures accompanied by autonomic signs.
Patients 5, 14, and 17 had clusters of infantile spasms recorded
on video-EEG, in addition to focal seizures (table). Their
interictal EEG showed hypsarrhythmia (figure 2). All patients
Glossary
ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; AED = antiepileptic drug; CZP = clonazepam; EIMFS =
epilepsy of infancy with migrating focal seizure; EOEE = early-onset epileptic encephalopathy; LTG = lamotrigine.
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had multiple daily seizures at the onset and continued to have
frequent seizures, resistant to 3 or more AED trials in the first
month to the first year of life (table).
EEG recorded at onset typically showed a migrating ictal
pattern (figure 2A), whereas interictal EEG showed a slow
background activity with lack of physiologic rhythms and
rare multifocal spikes or spike and waves. In patients 5, 8, 10,
and 11, migrating seizures preceded with a pattern of
“suppression burst” on EEG (figure 2B). All children had
long-lasting EEGs with ECG showing no cardiac rhythm
abnormalities with normal Holter ECG (24-hour recording)
in 5 patients.
Two patients (#4 and 9) were on the quinidine trial according
to a previously reported protocol.14 For patient 4, quinidine
was administered with lamotrigine (LTG), valproate, clona-
zepam (CZP), and a ketogenic diet at age 4 years, and for
patient 9, quinidine was administered with LTG and CZP at 2
years. A dose of 10 mg/kg/d was achieved gradually over 1
week. The quinidine serum level at 1 month was 0.7 and
0.6 μg/mL for patients 4 and 9, respectively. The dose was
increased over 1 week to 35 mg/kg/d in 3 divided doses. The
serum level increased gradually up to 3 and 2.7 μg/mL in
patients 4 and 9, respectively. After 1 month, we did not see
any effect on seizure frequency. ECGs were normal, and the
dose was increased a third time up to 50 mg/kg/d. After 2
weeks of this dose, the serum level of quinidine did not exceed
3 and 4.5 μg/mL for patients 4 and 9, respectively. This
treatment failed to decrease the number of countable seizures
(60 and 85 seizures per day for patients 4 and 9 over 3
months). Quinidine was provided at 35 mg/kg/d for the last 2
months. Neither seizure frequency nor EEG pattern showed
any significant change, and quinidine was therapy dis-
continued. During the quinidine trial, patients did not present
any noticeable side effects, and parents did not report any
changes in appetite, eye contact, or sleep behavior.
Mutation analysis
All patients carried heterozygous missense mutations: p.G288S
(#1), p.R398Q (#2), p.R428Q (#3, 4, 5, and 6), p.L437P (#7),
p.R474C (#8 and 9), p.R474H (#10 and 11), p.M516V (#12),
p.M896I (#13), p.A934T (#14 and 15), p.A965V (#16), and
p.R1106P (#17) (table, figure 3). We did not perform func-
tional studies for the novel p.A965V variant (#16), as it
modifies a strongly conserved amino acid and is predicted likely
pathogenic by in silico software (PolyPhen-2, SIFT, and
CADD). In addition, this mutation was not present in the
Genome Aggregation Database (gnomAD, gnomad.broad-
institute.org) and in-house databases. All the other mutations
have been reported previously, namely p.G288S, p.R398Q, and
p.A934T both in EIMFS and ADNFLE,3,4,8,9,13,17,22–27,30,31,36
p.R428Q and p.R474H in EIMFS and early-onset epileptic
encephalopathies,3–7 p.R474C and p.M516V in
EIMFS,7,21,25,28,29 p.M896I in ADNFLE,4 and p.R1106P in
Brugada syndrome.11 These KCNT1 mutations occur on the
C-terminal cytoplasmic domain, except for p.G288S affecting
the protein pore (#1). Many mutations are recurrent, namely
p.G288S (#1), p.R398Q (#2), p.R428Q (#3, 4, 5, and 6), and
p.A934T (#14 and 15) and arose de novo except the p.R398Q
inherited from the proband’s father affected by ADNFLE (#2).
The familial study showed the presence of the p.R398Q mu-
tation in a heterozygous state in both paternal uncles, one being
asymptomatic and the other presenting with a single tonic-
clonic seizure at 25 years (figure 1). The paternal grandfather,
likely affected by ADNFLE, could not be tested.
Genotype-phenotype correlation of our series
with literature review
We carefully reviewed 35 articles on patients with KCNT1
mutations and established the phenotype in 120 patients
from 116 families. Seventy-five presented with
EIMFS,3,7,9,13,14,16,17,20–22,24–32,34–37 33 with ADNFLE,4,9,35 4
with other focal seizures,10,16,24 4 with West syndrome,7,8,26,33
4 with early-onset epileptic encephalopathy (EOEE),6,7,15,36
and 1 with Brugada syndrome without epilepsy phenotype.11
A specific mutation can be reported in different phenotypes
and therefore is not possible to establish a genotype-
phenotype correlation based on single mutation or hot
spots (figure 3). For example, the p.G288S, the p.R398Q, and
the p.A934T mutations are present in both EIMFS and
ADNFLE.3,4,7,9,17,26
Discussion
In a cohort of 17 new patients, we report the association of
EIMFS with 1 novel mutation in the KCNT gene. The ma-
jority of the KCNT1 mutations cluster in the C-terminal
KCNT1 region, except for p.G288S on the channel pore, and
several variants in the transmembrane domain-5 (figure 3). Of
interest as confirmed in this series, several KCNT1 mutations
recur and occur in specific hot spots, namely p.G288S,
p.R398Q, p.R428Q, p.R474C, p.R474H, and p.A934T (figure
3).3,4,7,8,13,16,17,22–31,37 Hotspots are rarely reported in other
genes encoding K+ channels that are involved in de-
velopmental and epileptic encephalopathies. Notably, only 1
recurrent mutation identified in the KCNC1 voltage-gated
potassium channel is responsible for autosomal dominant
progressive myoclonic epilepsy phenotype.38 In contrast to
KCNC1, the same KCNT1 mutation may be involved in
several phenotypes (figure 3).
The “suppression burst” pattern was recorded on EEG in 4
patients before the “migrating” pattern, and 3 children had
infantile spasms during the disease with hypsarrhythmia.
Hypsarrhythmia pattern, usually present in early-onset epi-
leptic encephalopathy with suppression bursts, is rarely seen
in EIMFS.7 Our findings emphasize the overlap of the EEG
and seizure phenotypes of EOEE with EIMFS.
KCNT1 encodes the sodium-activated potassium channel
KCa4.1 (also called SLACK and Slo2.2) and is responsible
for the slow hyperpolarization following repetitive firing.
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KCNT1 is widely expressed in the nervous system and in
the dorsal root ganglia, kidney, and heart.3 Gain-of-
function KCNT1 variants emerged as a leading cause of
EIMFS, affecting about 50% of patients.3 Overall, in-
cluding the present study, about 150 patients harboring
KCNT1 mutations have been reported so far. The most
consistent KCNT1-related clinical phenotype in 120 cases
described with satisfactory clinical detail is EIMFS (55% of
patients).3–37 KCNT1 mutations are present in
ADNFLE,4,9,35 focal or multifocal epilepsies,9,10,16,24 and
other developmental and epileptic encephalopathies.5–8,15,33,37
KCNT1 variants are causal of a clinical phenotypic spectrum
because identical mutations can be associated with different
epileptic phenotypes (figure 3). The p.R398Q and p.R950Q
mutations were associated with intrafamilial variable expres-
sivity in 2 families where a child affected by EIMFS who
inherited the mutation from the father with ADNFLE-like
phenotype.9,17
Here, we report the occurrence of the p.R398Q mutation in
a large family resulting in various epilepsy phenotypes ranging
from the most severe form (EIMFS) to asymptomatic carrier,
with another family member presenting features of ADNFLE
phenotype. These observations of intrafamilial variable ex-
pressivity should prompt genetic counseling in families with
KCNT1 variants. Indeed, individuals harboring a KCNT1
mutation with fairly mild phenotype can transmit EIMFS, and
this should be considered in prenatal diagnosis. In addition,
the pathogenicity of KCNT1 variants inherited from un-
affected parents cannot be ruled out and should undertake
further functional studies.
The variable expressivity of KCNT1 mutations could extend
beyond the CNS. One patient (#17) in our series carries the
Figure 1 Pedigree of patient 2
The sign ± points to family members carrying the heterozygous c.1193G>A
KCNT1 pathogenic variant; −/− indicates the patients with wild-type variants.
Individual I2 presented nocturnal paroxysmal events, behavioral and psy-
chiatric disorders; II2, 30 years, had ADNFLE andwas seizure-free with AEDs;
II3, 36 years, had a single episode of TC seizure at age 25 years, average
intellect, and fair social and professional integration. II4, 34 years, healthy,
average intellect, and fair social and professional integration; III1 (proband)
had EIMFS (patient 2, table). ADNFLE = autosomal dominant nocturnal
frontal lobe epilepsy; AED = antiepileptic drug; EIMFS = epilepsy of infancy
with migrating focal seizures; NA = blood sample not available.
Figure 2 EEG recording of patient 9 at age 6 months
(A) Display of the migrating pattern. (B) Intermittent suppression burst pattern. (C) EEG recording of right hemispheric discontinuous background con-
comitant to left posterior rhythmic alpha discharge.
6 Neurology: Genetics | Volume 5, Number 6 | December 2019 Neurology.org/NG
p.R1106Q mutation, previously reported in a patient with
Brugada syndrome.11 The patient in this study showed no
cardiac rhythm abnormalities over 24 hours of Holter ECG
recording. Available data are not strong enough for clinical
recommendation on ECG surveillance, but a dedicated car-
diac rhythm study should be useful before initiating quinidine
treatment.
In this series, 2 patients carrying the p.R428Q and the p.R474C
mutation had treatment with the antiarrhythmic drug quinidine
according to a previously published protocol.14 Quinidine had
no side effects and showed good tolerance in both patients. In
particular, we did not observe an increase in the QTc interval
on treatment with quinidine until a dose of 40 mg/kg. How-
ever, quinidine did not reduce seizure frequency, despite
plasma levels within the therapeutic range.
Treatment with quinidine, a KCNT1 blocker, owing to its
ability to reverse the in vitro channel hyperactivity has been
considered a rational approach for seizure control in EIMFS.12
Targeted therapy with quinidine in few patients based on in
vitro results showed variable in vivo efficacy.8,13–16,18–21,30
Seizure reduction was absent in about 40% of patients har-
boring the KCNT1 mutation with EIMFS or other early-onset
developmental and epileptic encephalopathies (6/16, including
the present series). The neurodevelopmental prognosis was
altered marginally during quinidine treatment.20 Several fac-
tors, such as the mutation, the age at epilepsy onset, the age at
quinidine treatment, and pharmacokinetic and pharmacody-
namic factors such as blood-brain barrier penetration, account
for the observed heterogeneity.20 Response to quinidine
treatment did not correlate with a specific mutation due to
contradictory results observed in patients carrying the same
p.R428Q mutation.13,15
Although the initial results showed that early treatment is es-
sential for quinidine antiepileptic efficacy, with patients being
responsive only when starting treatment younger than 4
Figure 3 Schematic localization of KCNT1 mutations reported in this series and in previous studies
KCNT1 encodes the sodium-activated potassium channel KCa4.1 (also called SLACK and Slo2.2), composed by a short cytoplasmic N-terminal region, 6
transmembrane domains with a pore-forming region, and a large C-terminal region with 2 regulators of potassium conductance domains (RCK1 and RCK2).
Mutations associated with EIMFS shaded in yellow, and ADNFLE mutations shaded in light blue. Mutations involved in several phenotypes, including EIMFS
and ADNFLE, are indicated in blue. Mutations involved in phenotypes other than EIMFS and ADNFLE shaded in green. The size of each circle is proportional to
the number of reported patients (present series and previous report). ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; EIMFS = epilepsy of
infancy with migrating focal seizure.
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years,16,20 the recent results did not confirm this hypothesis,19,21
and this report shows quinidine inefficacy despite early treat-
ment initiation in 1 patient.
We hypothesize that quinidine does not improve the de-
velopmental issues because it did not affect the KCNT1
nonconducting functions. A constitutive hyperactivation of K
channels is the underlying pathophysiologic mechanism of
epileptogenesis and is attenuated by quinidine in vitro. Nev-
ertheless, KCNT1mutations impair not only the gating of the
channel but also its ability to interact with developmental
signaling proteins coupled to its C-terminus, such as fragile X
mental retardation-1 protein,3 thus identifying the KCNT1
nonconducting functions as a potential target of novel ther-
apeutic strategies. These results emphasize the difficulties of
bench-to-bed translational studies and the need for a pro-
spective randomized multicentric trial in patients with
KCNT1-related epilepsies.
Study funding
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